{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:28:10Z","timestamp":1777940890341,"version":"3.51.4"},"reference-count":32,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Shaanxi Provincial Key Research and Development Project of China","award":["2018SF-033"],"award-info":[{"award-number":["2018SF-033"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Technol Cancer Res Treat"],"published-print":{"date-parts":[[2019,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study aimed to investigate the effect of tetra-arsenic tetra-sulfide on treating multiple myeloma and its potential regulation on suppressor of cytokine signaling 1 methylation-mediated Janus kinase 2\/signal transducer and activator of transcription 3 signaling pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Tetra-arsenic tetra-sulfide with different concentrations were used to treat U266 cells, and cell viability was measured at 12, 24, and 48 hours with 0 \u03bcM tetra-arsenic tetra-sulfide treatment as control by Cell Counting Kit-8 assay. Suppressor of cytokine signaling 1 methylation and expression were determined by methylation-specific polymerase chain reaction, quantitative polymerase chain reaction, and Western blot, respectively, in U266 cells and normal plasma cells and in U266 cells treated by tetra-arsenic tetra-sulfide. Then, rescue experiments were performed by transfecting suppressor of cytokine signaling 1 small interfering RNA into tetra-arsenic tetra-sulfide-treated U266 cells. Besides, phosphor\u2013Janus kinase 2, Janus kinase 2, phospho\u2013signal transducer and activator of transcription 3, and signal transducer and activator of transcription 3 expressions were determined by Western blot.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Tetra-arsenic tetra-sulfide inhibited U266 cell viability efficiently in a dose- and time-dependent manner. Suppressor of cytokine signaling 1 methylation was higher while suppressor of cytokine signaling 1 expression was lower in U266 cells compared to normal plasma cells; when treated by tetra-arsenic tetra-sulfide, suppressor of cytokine signaling 1 methylation was decreased while suppressor of cytokine signaling 1 expression was increased in U266 cells, along with the reduced phospho\u2013Janus kinase 2 and phospho\u2013signal transducer and activator of transcription 3 expressions. Then, suppressor of cytokine signaling 1 small interfering RNA enhanced the cell viability and phospho\u2013Janus kinase 2 as well as phospho\u2013signal transducer and activator of transcription 3 expressions in both tetra-arsenic tetra-sulfide treatment-free and tetra-arsenic tetra-sulfide-treated U266 cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Tetra-arsenic tetra-sulfide exhibits good killing effect on multiple myeloma cells via repressing suppressor of cytokine signaling 1 methylation and downstream Janus kinase 2\/signal transducer and activator of transcription 3 signaling pathway, which might serve as a potential treatment option for multiple myeloma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1533033819896806","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T08:05:27Z","timestamp":1577088327000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["As\n                    <sub>4<\/sub>\n                    S\n                    <sub>4<\/sub>\n                    Exhibits Good Killing Effect on Multiple Myeloma Cells Via Repressing SOCS1 Methylation-Mediated JAK2\/STAT3 Signaling Pathway"],"prefix":"10.1177","volume":"18","author":[{"given":"Di","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Sales, Kindstar Global, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Sales, Kindstar Global, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9770-5231","authenticated-orcid":false,"given":"Mengchang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,12,23]]},"reference":[{"key":"bibr1-1533033819896806","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2016.10.069"},{"key":"bibr2-1533033819896806","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-007-0606-z"},{"key":"bibr3-1533033819896806","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-568915"},{"key":"bibr4-1533033819896806","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60493-1"},{"key":"bibr5-1533033819896806","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.11.020"},{"key":"bibr6-1533033819896806","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2017.09.007"},{"key":"bibr7-1533033819896806","doi-asserted-by":"publisher","DOI":"10.1097\/00029330-200607020-00018"},{"issue":"2","key":"bibr8-1533033819896806","first-page":"243","volume":"25","author":"Wang MC","year":"2006","journal-title":"J Exp Clin Cancer Res"},{"key":"bibr9-1533033819896806","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130343"},{"key":"bibr10-1533033819896806","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1433"},{"key":"bibr11-1533033819896806","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-013-1452-1"},{"key":"bibr12-1533033819896806","doi-asserted-by":"publisher","DOI":"10.1038\/srep29348"},{"key":"bibr13-1533033819896806","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S180976"},{"key":"bibr14-1533033819896806","doi-asserted-by":"publisher","DOI":"10.1038\/srep19793"},{"issue":"5","key":"bibr15-1533033819896806","first-page":"1064","volume":"16","author":"Wang MM","year":"2008","journal-title":"Zhongguo shi yan xue ye xue za zhi"},{"issue":"7","key":"bibr16-1533033819896806","first-page":"755","volume":"19","author":"Liu L","year":"2016","journal-title":"Iran J Basic Med Sci"},{"issue":"2","key":"bibr17-1533033819896806","first-page":"170","volume":"16","author":"Xu W","year":"2019","journal-title":"Iran J Immunol"},{"key":"bibr18-1533033819896806","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21973"},{"key":"bibr19-1533033819896806","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17175"},{"key":"bibr20-1533033819896806","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2014.2838"},{"key":"bibr21-1533033819896806","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00333"},{"key":"bibr22-1533033819896806","doi-asserted-by":"publisher","DOI":"10.3892\/br.2015.466"},{"key":"bibr23-1533033819896806","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2015.3217"},{"key":"bibr24-1533033819896806","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.899214"},{"key":"bibr25-1533033819896806","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00020"},{"key":"bibr26-1533033819896806","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2007"},{"issue":"2","key":"bibr27-1533033819896806","first-page":"1008","volume":"40","author":"Zhang XH","year":"2018","journal-title":"Oncol Rep"},{"key":"bibr28-1533033819896806","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069090"},{"key":"bibr29-1533033819896806","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2014.15.11.4555"},{"issue":"115","key":"bibr30-1533033819896806","author":"Liu K","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"bibr31-1533033819896806","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2018.07.010"},{"issue":"7","key":"bibr32-1533033819896806","first-page":"3169","volume":"8","author":"Zhao S","year":"2016","journal-title":"Am J Transl Res"}],"container-title":["Technology in Cancer Research &amp; Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1533033819896806","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1533033819896806","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1533033819896806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:04:33Z","timestamp":1777701873000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1533033819896806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,1]]},"references-count":32,"alternative-id":["10.1177\/1533033819896806"],"URL":"https:\/\/doi.org\/10.1177\/1533033819896806","relation":{},"ISSN":["1533-0346","1533-0338"],"issn-type":[{"value":"1533-0346","type":"print"},{"value":"1533-0338","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,1]]},"article-number":"1533033819896806"}}